https://www.nasdaq.com/press-release/argenx-to-present-at-40th-annual-j.p.-morgan-healthcare-conference-2022-01-03
https://www.nasdaq.com/press-release/zai-lab-partner-argenx-announces-u.s.-food-and-drug-administration-fda-approval-of
https://www.nasdaq.com/press-release/argenx-announces-u.s.-food-and-drug-administration-fda-approval-of-vyvgarttm
https://www.nasdaq.com/press-release/argenx-to-present-at-upcoming-investor-conferences-2021-11-10
https://www.nasdaq.com/press-release/argenx-reports-third-quarter-2021-financial-results-and-provides-business-update-2021
https://www.nasdaq.com/press-release/argenx-to-report-third-quarter-2021-financial-results-and-business-update-on-october
https://www.nasdaq.com/press-release/argenx-to-highlight-potential-first-in-class-fcrn-antagonist-efgartigimod-at-upcoming
https://www.nasdaq.com/press-release/argenx-to-present-at-upcoming-investor-conferences-2021-09-03
https://www.nasdaq.com/press-release/argenx-announces-validation-of-european-marketing-authorization-application-for
https://www.nasdaq.com/press-release/argenx-to-present-at-2021-wedbush-pacgrow-virtual-healthcare-conference-2021-08-04
https://www.nasdaq.com/press-release/argenx-reports-half-year-2021-financial-results-and-provides-second-quarter-business
https://www.nasdaq.com/press-release/argenx-to-report-half-year-2021-financial-results-and-second-quarter-business-update
https://www.nasdaq.com/press-release/argenx-to-host-virtual-rd-day-on-july-20-2021-2021-07-14
https://www.nasdaq.com/press-release/argenx-announces-publication-of-phase-3-adapt-trial-results-of-efgartigimod-for-the
https://www.nasdaq.com/press-release/argenx-to-regain-global-rights-to-cusatuzumab-2021-06-07
https://www.nasdaq.com/press-release/argenx-appoints-karl-gubitz-as-chief-financial-officer-2021-06-01
https://www.nasdaq.com/press-release/argenx-to-present-at-upcoming-investor-conferences-2021-06-01
https://www.nasdaq.com/press-release/argenx-reports-first-quarter-2021-financial-results-and-provides-business-update-2021
https://www.nasdaq.com/press-release/argenx-announces-results-of-annual-general-meeting-of-shareholders-2021-05-11
https://www.nasdaq.com/press-release/argenx-to-report-first-quarter-2021-financial-results-and-business-update-on-may-14
https://www.nasdaq.com/press-release/argenx-management-to-present-at-upcoming-virtual-investor-conferences-2021-04-28
https://www.nasdaq.com/press-release/argenx-announces-annual-general-meeting-of-shareholders-on-may-11-2021-2021-03-30
https://www.nasdaq.com/press-release/argenx-reports-full-year-2020-financial-results-and-provides-fourth-quarter-business
https://www.nasdaq.com/press-release/argenx-announces-fda-acceptance-of-bla-filing-for-efgartigimod-for-the-treatment-of
https://www.nasdaq.com/press-release/argenx-to-report-full-year-2020-financial-results-and-fourth-quarter-business-update
https://www.nasdaq.com/press-release/argenx-announces-closing-of-global-offering-2021-02-05
https://www.nasdaq.com/press-release/argenx-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-1
https://www.nasdaq.com/press-release/argenx-raises-%241.0-billion-in-gross-proceeds-in-a-global-offering-2021-02-02
https://www.nasdaq.com/press-release/argenx-issues-statement-concerning-efgartigimod-2021-02-02
https://www.nasdaq.com/press-release/argenx-announces-launch-of-proposed-global-offering-2021-02-01
https://www.nasdaq.com/press-release/argenx-announces-go-decision-in-adhere-trial-of-efgartigimod-in-chronic-inflammatory
https://www.nasdaq.com/press-release/argenx-announces-2021-corporate-priorities-and-highlights-recent-achievements-across
https://www.nasdaq.com/press-release/argenx-and-zai-lab-announce-strategic-collaboration-for-efgartigimod-in-greater-0
https://www.nasdaq.com/press-release/argenx-and-zai-lab-announce-strategic-collaboration-for-efgartigimod-in-greater-china
https://www.nasdaq.com/press-release/argenx-enters-into-agreement-to-acquire-priority-review-voucher-2020-11-23
https://www.nasdaq.com/press-release/argenx-premieres-a-mystery-to-me-a-docuseries-inspired-by-the-myasthenia-gravis
https://www.nasdaq.com/press-release/argenx-to-participate-in-upcoming-virtual-investor-conferences-2020-11-09
https://www.nasdaq.com/press-release/argenx-reports-third-quarter-2020-financial-results-and-provides-business-update-2020
https://www.nasdaq.com/press-release/argenx-to-report-third-quarter-2020-financial-results-and-business-update-on-october
https://www.nasdaq.com/press-release/argenx-expands-capabilities-in-antibody-engineering-through-key-technology
